P-119 The Effectiveness of Treatment of Patients with Crohn's Disease Mesenchymal Stromal Cells—7 Years of Observation

    loading  Checking for direct PDF access through Ovid



Anticytokine therapy with anti-TNF-alpha drugs contributes to the achievement of stable remission of Crohn's disease (CD). For the treatment of CD are also using mesenchymal stromal cells (MSCs).


To examine the long-term efficacy (7 yr) therapy mesenchymal stromal cells (MSCs) from the bone marrow of patients with luminal Crohn's disease (CD).


Eighty patients with luminal form CD (terminal ileitis, colitis and ileokolit) were divided into 2 groups. The first group of patients aged 19 to 58 years old (Me-29) (n = 34) received the culture of MSCs under the scheme (0-1-2-3, then every 26 wk). The second group of patients with CD (n = 46) aged 20 to 62 years (ME-28) received standard anti-inflammatory therapy with 5-aminosalicylic acid (5-ASA), glucocorticosteroids (GCS) and immunosuppressive (IS). Evaluation of the effectiveness of therapy on the level of the index of activity of Crohn's disease (CDAI <150 point) was carried out at 12, 24, 36, 48, 60, 72 and 84 months after initiation of therapy.


Among the patients in 1-st group relapse in the 12 months of observation occurred in 4/36 patients (11.76%). In 2-st group, relapse occurred in 5/46 (10.8%) (P = 0.82). After 24 months in the 1-st group of patients receiving MSC, relapse occurred in 6/34 (17.6%). In the 2-nd group of patients relapse in 19/27 (41.3%) (P = 0.044). After 36 months in 1-st group patients with a relapse of the disease in 11/34 (32.3%). In the 2-nd group relapse 29/46 (63.1%) (P = 0.01). After 48 months in 1-st group, receiving MSCs, relapsed in 15/34 (44.1%). In the 2-nd group relapse in 33/46 (71.7%) (P = 0.023). After 60 months in the first group relapse in 19/34 (55.9%). In the second group relapse 40/46 (86.9%) (P = 0.004). After 72 months in first group relapse 25/34 (73.5%). In second group relapse of the CD in 45/46 (97.8%) (P = 0.001). After 84 months in first group relapse CD in 29/34 (85.3%). In the second group of patients CD relapse occurred in 46/46 (100.0%) (P = 0.011).


Mesenchymal stromal cells transplantation helps to maintain a long-term clinical remission in patients with luminal Crohn's disease compared with GCS/IS therapy.

Related Topics

    loading  Loading Related Articles